Sex-Specific Adverse Events and Cardiovascular Toxicity of Cabozantinib in Renal Cell Carcinoma: A Nine-Year Pharmacovigilance Study
{{output}}
Background: Cabozantinib is a multi-target tyrosine kinase inhibitor widely used in advanced renal cell carcinoma (RCC). However, real-world evidence regarding its safety profile, particularly sex-specific adverse events (AEs) an... ...